| Browse All

AbCellera Biologics Inc. (ABCL)

Healthcare | Biotechnology | Vancouver, Canada | NasdaqGS
3.91 USD +3.91 (-2.494%) ⇧ (April 20, 2026, 4 p.m. EDT)

Short-term: ★★★☆☆ | Long-term: ☆☆☆☆☆ | Dividends: ☆☆☆☆☆
Hot Take | April 19, 2026, 1:05 a.m. EDT

AbCellera is a speculative biotech dime store played on the hope for a 10x base gene therapy underlying, but the data paints a deterioration picture: negative earnings, negative free cash flow, negative gross margins, and a firmament founded on high PE and debt. With a short ratio of 18x and no dividends, the risk is extreme. The long-term outlook is a buy trap, but the short-term momentum is supported by aggressive call speculation despite the negative statistical forecast.

Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
AutoARIMA ✓0.150758
AutoTheta0.153385
AutoETS0.153432
MSTL0.166342

Forecast horizon: 45 days | Selected: AutoARIMA

Forecast Reliability
Score 80%
H-stat 0.41
Ljung-Box p 0.000
Jarque-Bera p 0.407
Excess Kurtosis 0.13
Attribute Value
Sector Healthcare
Debt to Equity Ratio 14.812
Revenue per Share 0.252
Market Cap 1,185,357,440
Forward P/E -4.99
Beta 0.85
Profit Margins -194.88%
Website https://www.abcellera.com

As of April 19, 2026, 1:05 a.m. EDT: Options flow is dominated by deep Out-of-The-Money (OTM) long calls (6.0 and 7.0 strikes) with high implied volatility, suggesting aggressive speculative speculation on a significant upside move to targets around $7+. However, significant Put OI clings to OTM strikes (3.0 and 2.0 in longer tenors), indicating a hedge against downside. Notably, the 10-exp has seen new flow into 4.0 strikes for puts, suggesting some near-term defensive positioning as the stock approaches $4. The 45-day adjusted forecast predicts -3.46% downside, conflicting slightly with the call-heavy flow but weighted heavily towards continuation of recent volatility.


Info Dump

Attribute Value
52 Week Change 0.55158734
Address1 150 W 4th Avenue
All Time High 71.91
All Time Low 1.891
Ask 3.94
Ask Size 14
Audit Risk 7
Average Analyst Rating 1.3 - Strong Buy
Average Daily Volume10 Day 3,292,920
Average Daily Volume3 Month 3,564,370
Average Volume 3,564,370
Average Volume10Days 3,292,920
Beta 0.846
Bid 3.89
Bid Size 16
Board Risk 9
Book Value 3.217
City Vancouver
Compensation As Of Epoch Date 1,735,603,200
Compensation Risk 7
Country Canada
Crypto Tradeable 0
Currency USD
Current Price 3.91
Current Ratio 11.324
Custom Price Alert Confidence HIGH
Date Short Interest 1,774,915,200
Day High 4.03
Day Low 3.88
Debt To Equity 14.812
Display Name AbCellera Biologics
Earnings Call Timestamp End 1,778,533,200
Earnings Call Timestamp Start 1,778,533,200
Earnings Timestamp 1,778,529,600
Earnings Timestamp End 1,778,529,600
Earnings Timestamp Start 1,778,529,600
Ebitda -194,932,000
Ebitda Margins -2.59467
Enterprise To Ebitda -4.077
Enterprise To Revenue 10.579
Enterprise Value 794,749,504
Eps Current Year -0.7075
Eps Forward -0.78333
Eps Trailing Twelve Months -0.49
Esg Populated 0
Exchange NMS
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fifty Day Average 3.4398
Fifty Day Average Change 0.47020006
Fifty Day Average Change Percent 0.13669401
Fifty Two Week Change Percent 55.158733
Fifty Two Week High 6.515
Fifty Two Week High Change -2.6049998
Fifty Two Week High Change Percent -0.3998465
Fifty Two Week Low 1.94
Fifty Two Week Low Change 1.97
Fifty Two Week Low Change Percent 1.015464
Fifty Two Week Range 1.94 - 6.515
Financial Currency USD
First Trade Date Milliseconds 1,607,697,000,000
Float Shares 206,791,831
Forward Eps -0.78333
Forward P E -4.9915104
Free Cashflow -175,997,376
Full Exchange Name NasdaqGS
Full Time Employees 562
Gmt Off Set Milliseconds -14,400,000
Governance Epoch Date 1,775,001,600
Gross Margins -1.48681
Gross Profits -111,701,000
Has Pre Post Market Data 1
Held Percent Insiders 0.22752
Held Percent Institutions 0.37341
Implied Shares Outstanding 303,160,487
Industry Biotechnology
Industry Disp Biotechnology
Industry Key biotechnology
Ipo Expected Date 2,020-12-11
Is Earnings Date Estimate 0
Language en-US
Last Fiscal Year End 1,767,139,200
Long Business Summary AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.
Long Name AbCellera Biologics Inc.
Market us_market
Market Cap 1,185,357,440
Market State PRE
Max Age 86,400
Message Board Id finmb_280568380
Most Recent Quarter 1,767,139,200
Net Income To Common -146,412,000
Next Fiscal Year End 1,798,675,200
Non Diluted Market Cap 1,185,357,504
Number Of Analyst Opinions 7
Open 4.015
Operating Cashflow -131,295,000
Operating Margins -0.63724
Overall Risk 7
Payout Ratio 0.0
Phone 604 559 9005
Pre Market Change 0.1547997
Pre Market Change Percent 3.9590716
Pre Market Price 4.0648
Pre Market Time 1,776,759,395
Previous Close 0.0
Price Eps Current Year -5.526502
Price Hint 4
Price To Book 1.2154181
Price To Sales Trailing12 Months 15.777839
Profit Margins -1.94883
Quick Ratio 10.074
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key strong_buy
Recommendation Mean 1.33333
Region US
Regular Market Change 3.91
Regular Market Change Percent -2.49377
Regular Market Day High 4.03
Regular Market Day Low 3.88
Regular Market Day Range 3.88 - 4.03
Regular Market Open 4.015
Regular Market Previous Close 0.0
Regular Market Price 3.91
Regular Market Time 1,776,715,201
Regular Market Volume 5,197,809
Return On Assets -0.09986
Return On Equity -0.14475
Revenue Growth 7.882
Revenue Per Share 0.252
Sand P52 Week Change 0.34445214
Sector Healthcare
Sector Disp Healthcare
Sector Key healthcare
Share Holder Rights Risk 5
Shares Outstanding 303,160,487
Shares Percent Shares Out 0.1663
Shares Short 50,425,478
Shares Short Previous Month Date 1,772,150,400
Shares Short Prior Month 51,320,387
Short Name AbCellera Biologics Inc.
Short Percent Of Float 0.2149
Short Ratio 18.79
Source Interval 15
State BC
Symbol ABCL
Target High Price 12.0
Target Low Price 7.0
Target Mean Price 9.42857
Target Median Price 10.0
Total Cash 533,825,984
Total Cash Per Share 1.761
Total Debt 143,218,000
Total Revenue 75,128,000
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield NaN
Trailing Eps -0.49
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 4.1356
Two Hundred Day Average Change -0.2256
Two Hundred Day Average Change Percent -0.05455073
Type Disp Equity
Volume 5,197,809
Website https://www.abcellera.com
Zip V5Y 1G6